 NEW YORK--BUSINESS WIRE--Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7 of Acceleron Pharma Inc. Nasdaq: XLRN Acceleron, XLRN or the Company together with certain of its affiliates and managed funds Avoro, we or us, making it one of the Companys most significant shareholders. Avoro today issued the following statement: Despite the fact that Avoro believes that Accelerons management team 